Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent

BACKGROUND: CYT997 is a novel microtubule inhibitor and vascular-disrupting agent with marked preclinical anti-tumour activity. METHODS: This phase I dose-escalation study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of CYT997 administered by continuous intravenous infusi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lickliter, J D, Francesconi, A B, Smith, G, Burge, M, Coulthard, A, Rose, S, Griffin, M, Milne, R, McCarron, J, Yeadon, T, Wilks, A, Cubitt, A, Wyld, D K, Vasey, P A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938266/
https://www.ncbi.nlm.nih.gov/pubmed/20733579
http://dx.doi.org/10.1038/sj.bjc.6605841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938266/
https://www.ncbi.nlm.nih.gov/pubmed/20733579
http://dx.doi.org/10.1038/sj.bjc.6605841

Ejemplares similares